Filtered By:
Condition: Pulmonary Thromboembolism
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 2761 results found since Jan 2013.
Incidence of Thromboembolic Complications Following Kidney Transplantation with Short and Extended Aspirin Prophylaxis: A Retrospective Single-Center Study
CONCLUSIONS Extended-duration aspirin use did not significantly reduce the incidence of VTE in the first 6 weeks following kidney transplantation. An association was identified between anti-human thymocyte immunoglobulin and VTE, which requires further assessment.PMID:37309097 | DOI:10.12659/AOT.939143
Source: Annals of Transplantation - June 13, 2023 Category: Transplant Surgery Authors: Angus H Pegler Katharine Hegerty Ryan P Gately Carmel M Hawley David W Johnson Yeoungjee Cho Dev K Jegatheesan Andrew B McCann Michelle E Harfield Nicole M Isbel Source Type: research
NET-(works) in arterial and venous thrombo-occlusive diseases
Front Cardiovasc Med. 2023 May 22;10:1155512. doi: 10.3389/fcvm.2023.1155512. eCollection 2023.ABSTRACTFormation of Neutrophil Extracellular Traps (NETosis), accompanied by the release of extracellular decondensed chromatin and pro-inflammatory as well as pro-thrombotic factors, is a pivotal element in the development and progression of thrombo-occlusive diseases. While the process of NETosis is based on complex intracellular signalling mechanisms, it impacts a wide variety of cells including platelets, leukocytes and endothelial cells. Consequently, although initially mainly associated with venous thromboembolism, NETs al...
Source: Atherosclerosis - June 7, 2023 Category: Cardiology Authors: Monika Zdanyte Oliver Borst Patrick M ünzer Source Type: research
Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures
CONCLUSIONS: We cannot draw conclusions from the current evidence due to lack of data. Most published studies included in our analyses assessed the use of tranexamic acid (compared to placebo, or using different routes of administration). We identified 27 prospectively registered ongoing RCTs (total target recruitment of 4177 participants by end of 2023). The ongoing trials create six new comparisons: tranexamic acid (tablet + injection) versus placebo; intravenous tranexamic acid versus oral tranexamic acid; topical tranexamic acid versus oral tranexamic acid; different intravenous tranexamic acid dosing regimes; topical ...
Source: Cochrane Database of Systematic Reviews - June 5, 2023 Category: General Medicine Authors: Victoria N Gibbs Rita Champaneria Louise J Geneen Parag Raval Carolyn Dor ée Susan J Brunskill Alex Novak Antony Jr Palmer Lise J Estcourt Source Type: research
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis
Clin Exp Vaccine Res. 2023 Apr;12(2):172-175. doi: 10.7774/cevr.2023.12.2.172. Epub 2023 Apr 30.ABSTRACTCoronavirus disease 2019 (COVID-19) has become a part of our lives now and we have no more effective way of coping than a vaccine. COVID-19 is a disease that causes severe thrombosis outside the respiratory tract. Vaccines also protect us in this respect, but in some rare cases, thrombosis has been found to develop after vaccination (much less frequently than COVID-19). What was interesting in our case was that it showed how a disaster could happen under three factors that predispose to thrombosis. A 65-year-old female p...
Source: Atherosclerosis - May 22, 2023 Category: Cardiology Authors: Vecihe Bayrak Source Type: research
Bucks County company's catheter invented at Temple med school gets FDA OK
The catheter is designed to treat acute pulmonary embolism, the third leading cause of cardiovascular death after heart attack and stroke.
Source: bizjournals.com Health Care News Headlines - May 15, 2023 Category: Health Management Authors: John George Source Type: news
Identification, characterization, and engineering of glycosylation in thrombolyticsa
Biotechnol Adv. 2023 May 12:108174. doi: 10.1016/j.biotechadv.2023.108174. Online ahead of print.ABSTRACTCardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary embolism, are the most common causes of disability and death worldwide. Blood clot hydrolysis by thrombolytic enzymes and thrombectomy are key clinical interventions. The most widely used thrombolytic enzyme is alteplase, which has been used in clinical practice since 1986. Another clinically used thrombolytic protein is tenecteplase, which has modified epitopes and engineered glycosylation sites, suggesting that carbohydrate modifica...
Source: Biotechnology Advances - May 14, 2023 Category: Biotechnology Authors: Martin Toul Veronika Slonkova Jan Mican Adam Urminsky Maria Tomkova Erik Sedlak David Bednar Jiri Damborsky Lenka Hernychova Zbynek Prokop Source Type: research
Perioperative adverse cardiac events and mortality after non-cardiac surgery: a multicenter study
CONCLUSIONS: A nationwide multicenter study showed that PACE was significantly associated with increased one-year mortality. This association was stronger in high-risk surgery, older, male, and chronic kidney disease subgroups. Further studies to improve mortality associated with PACE are needed.PMID:37169362 | DOI:10.4097/kja.23043
Source: Korean Journal of Anesthesiology - May 11, 2023 Category: Anesthesiology Authors: Byungjin Choi Ah Ran Oh Jungchan Park Jong-Hwan Lee Kwangmo Yang Dong Yun Lee Sang Youl Rhee Sang-Soo Kang Seung Do Lee Sun Hack Lee Chang Won Jeong Bumhee Park Soobeen Seol Rae Woong Park Seunghwa Lee Source Type: research
